ABSTRACT
Prion diseases are caused by the propagation of PrPSc, the pathological conformation of the PrPC prion protein. The molecular mechanisms underlying PrPSc propagation are still unsolved and no therapeutic solution is currently available. We thus sought to identify new anti-prion molecules and found that flunarizine inhibited PrPSc propagation in cell culture and significantly prolonged survival of prion-infected mice. Using an in silico therapeutic repositioning approach based on similarities with flunarizine chemical structure, we tested azelastine, duloxetine, ebastine, loperamide and metixene and showed that they all have an anti-prion activity. Like flunarizine, these marketed drugs reduced PrPSc propagation in cell culture and in mouse cerebellum organotypic slice culture, and inhibited the protein folding activity of the ribosome (PFAR). Strikingly, some of these drugs were also able to alleviate phenotypes due to PABPN1 nuclear aggregation in cell and Drosophila models of oculopharyngeal muscular dystrophy (OPMD). These data emphasize the therapeutic potential of anti-PFAR drugs for neurodegenerative and neuromuscular proteinopathies.
Subject(s)
Drug Delivery Systems/methods , Flunarizine/administration & dosage , Poly(A)-Binding Protein I/metabolism , Prion Diseases/metabolism , Protein Aggregates/drug effects , Protein Folding/drug effects , Animals , Calcium Channel Blockers/administration & dosage , Cell Line , Databases, Factual , Drosophila , Female , Mice , Mice, Transgenic , Organ Culture Techniques , Poly(A)-Binding Protein I/antagonists & inhibitors , Poly(A)-Binding Protein I/genetics , Prion Diseases/drug therapy , Prion Diseases/genetics , Prion Proteins/antagonists & inhibitors , Prion Proteins/genetics , Prion Proteins/metabolism , Protein Aggregates/physiology , SheepABSTRACT
No disponible
Subject(s)
Humans , Male , Adult , Migraine Disorders/drug therapy , Acetazolamide/administration & dosage , Optic Chiasm/diagnostic imaging , Vestibular Diseases/diagnostic imaging , Flunarizine/administration & dosage , Nystagmus, Pathologic/diagnosis , Magnetic Resonance Spectroscopy , Pituitary Neoplasms/diagnosis , Optic Chiasm/surgery , Endoscopy , Migraine Disorders/diagnosis , Vestibular Diseases/classification , Dizziness/diagnosisABSTRACT
We developed a safe and efficacious drug delivery system for treatment of brain diseases. A novel in-situ gel system was prepared using soybean oil, stearic acid and N-methyl-2-pyrrolidinone (NMP) (10:1:3, v/w/v). This system had low viscosity as a sol in vitro and turned into a solid or semi-solid gel in situ after administration. The poorly water-soluble drug flunarizine hydrochloride (FNZ) was incorporated into this "organogel" system. Organogel-FNZ was characterized by light microscopy, differential scanning calorimetry (DSC) and rheology. Drug release in vitro was investigated. The initial "burst" effect did not occur in organogel-FNZ, which is different from other gels formed in situ. Pharmacokinetic studies were undertaken in rats using gel administration (14 mg kg-1), intravenous administration (5 mg kg-1) and administration using drops (14 mg kg-1). Organogel-FNZ could reduce the clearance rate and prolong the duration of action, in the plasma and brain tissues of rats. The peak serum concentration, area under the curve and absolute bioavailability of the organogel-FNZ group were higher than those of the intraocular- drops group. Organogel-FNZ is a promising drug-delivery system for treatment of brain diseases by intraocular administration.
Subject(s)
Drug Carriers , Flunarizine/administration & dosage , Pyrrolidinones/chemistry , Soybean Oil/chemistry , Stearic Acids/chemistry , Administration, Intravenous , Administration, Ophthalmic , Animals , Biological Availability , Drug Compounding , Drug Liberation , Flunarizine/chemistry , Flunarizine/pharmacokinetics , Gels , Male , Ophthalmic Solutions , Rabbits , Rats, Sprague-Dawley , ViscosityABSTRACT
BACKGROUND: Activation of peripheral and/or central trigeminovascular pain pathways are implicated in the pathogenesis of migraine. Small fibers mediate pain, thermal sensation, and autonomic functions. Axon flare response is correlated with local C-fiber activation and calcitonin gene-related peptide release. Laser speckle contrast analysis (LASCA) detects very subtle microcirculatory changes that are not visible to the naked eye. CASE: Axon flare response was elicited by 0.01 mL intradermal (i.d.) histamine introduced to the left forehead, trigeminal nerve ophthalmic branch (V1) skin area. Skin microvascular blood flow data were recorded using a LASCA real-time microcirculation imaging system. In the healthy control, prick stimulus slightly elevated focal skin microcirculation only at the stimulated focal area. However, in our patient with chronic migraine, the unilateral prick stimulation transiently (over 10 to 12 seconds) increased ipsilateral skin microcirculation at all 3 branches of the trigeminal nerve, with a slight expansion across the midline. Left V1 stimulation by i.d. histamine induced not only prominent but also long-lasting (10 to 15 minutes of recording time) axon flare response at the ipsilateral V1, V2, and V3 areas, with an expansion to the contralateral V1 area and without any report of allodynia or hyperalgesia. The treatment decreased axon flare characteristics probably by inhibiting neurogenic inflammation. DISCUSSION: The clinical characteristics and individual response to treatment vary widely across patients with pain. Here, we demonstrated the presence of transient spread of increased microcirculation at the ipsilateral trigeminal nerve, and also across the midline after prick stimulus, whereas a more prominent, widespread, and long-lasting histamine-induced axon flare response occurred in a rare subclass of patient who had chronic migraine with autonomic symptoms. The modulatory effect of the pharmacological intervention has also been objectively quantified by LASCA.
Subject(s)
Histamine/administration & dosage , Hyperalgesia/diagnosis , Migraine Disorders/diagnosis , Perfusion Imaging/methods , Thermography/methods , Trigeminal Nerve , Adult , Chronic Disease , Female , Flunarizine/administration & dosage , Histamine/adverse effects , Histamine H1 Antagonists/administration & dosage , Humans , Hyperalgesia/drug therapy , Hyperalgesia/physiopathology , Microcirculation/drug effects , Microcirculation/physiology , Migraine Disorders/drug therapy , Migraine Disorders/physiopathology , Trigeminal Nerve/drug effects , Trigeminal Nerve/physiopathologyABSTRACT
BACKGROUND: The sudden loss of blood supply in ischemic stroke is associated with an increase of calcium ions within neurons. Inhibiting this increase could protect neurons and might reduce neurological impairment, disability, and handicap after stroke. OBJECTIVES: To assess the effects of calcium antagonists for reducing the risk of death or dependency after acute ischemic stroke. We investigated the influence of different drugs, dosages, routes of administration, time intervals after stroke, and trial design on the outcomes. SEARCH METHODS: The evidence is current to 6 February 2018. We searched the Cochrane Stroke Group Trials Register (6 February 2018), Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 2), MEDLINE Ovid (1950 to 6 February 2018), Embase Ovid (1980 to 6 February 2018), and four Chinese databases (6 February 2018): Chinese Biological Medicine Database (CBM-disc), China National Knowledge Infrastructure (CNKI), Chinese Scientific Periodical Database of VIP information, and Wanfang Data. We also searched the following trials registers: ClinicalTrials.gov, EU Clinical Trials Register, Stroke Trials Registry, ISRCTN registry, WHO International Clinical Trials Registry Platform, and Chinese Clinical Trial Registry, and we contacted trialists and researchers. SELECTION CRITERIA: Randomized controlled trials comparing a calcium antagonist versus control in people with acute ischemic stroke. DATA COLLECTION AND ANALYSIS: Two review authors independently selected trials, extracted data, assessed risk of bias, and applied the GRADE approach to assess the quality of the evidence. We used death or dependency at the end of long-term follow-up (at least three months) in activities of daily living as the primary outcome. We used standard Cochrane methodological procedures. MAIN RESULTS: We included 34 trials involving 7731 participants. All the participants were in the acute stage of ischemic stroke, and their age ranged from 18 to 85 years, with the average age ranging from 52.3 to 74.6 years across different trials. There were more men than women in most trials. Twenty-six trials tested nimodipine, and three trials assessed flunarizine. One trial each used isradipine, nicardipine, PY108-608, fasudil, and lifarizine. More than half of these trials followed participants for at least three months. Calcium antagonists showed no effects on the primary outcome (risk ratio (RR) 1.05; 95% confidence interval (CI) 0.98 to 1.13; 22 trials; 22 studies; 6684 participants; moderate-quality evidence) or on death at the end of follow-up (RR 1.07, 95% CI 0.98 to 1.17; 31 trials; 7483 participants; moderate-quality evidence). Thirteen trials reported adverse events, finding no significant differences between groups. Most trials did not report the allocation process or how they managed missing data, so we considered these at high risk of selection and attrition bias. Most trials reported double-blind methods but did not state who was blinded, and none of the trial protocols were available. AUTHORS' CONCLUSIONS: We found no evidence to support the use of calcium antagonists in people with acute ischemic stroke.
Subject(s)
Brain Ischemia/drug therapy , Calcium Channel Blockers/therapeutic use , Stroke/drug therapy , Vasodilator Agents/therapeutic use , Acute Disease , Adult , Aged , Aged, 80 and over , Brain Ischemia/mortality , Calcium/metabolism , Calcium Channel Blockers/administration & dosage , Calcium Channel Blockers/adverse effects , Female , Flunarizine/administration & dosage , Flunarizine/adverse effects , Flunarizine/therapeutic use , Humans , Isradipine/administration & dosage , Isradipine/adverse effects , Isradipine/therapeutic use , Male , Middle Aged , Nimodipine/administration & dosage , Nimodipine/adverse effects , Nimodipine/therapeutic use , Randomized Controlled Trials as Topic , Vasodilator Agents/administration & dosage , Young AdultABSTRACT
BACKGROUND: Children with Sturge-Weber syndrome can experience severe headache with or without transient hemiparesis. Flunarizine, a calcium antagonist, has been used for migraine. The experience with flunarizine for headache in a cohort of children at a national center for Sturge-Weber syndrome is reviewed, reporting its efficacy and adverse effect in this population. METHODS: We collected data from health care professionals' documentation on headache (severity, frequency, duration) before and on flunarizine in 20 children with Sturge-Weber syndrome. Adverse effects reported during flunarizine treatment were collated. The Wilcoxon signed rank test was used to determine the significance of pre- versus post-treatment effect. RESULTS: Flunarizine was used for headache alone (13) or mixed migrainous episodes and vascular events (7). The median duration of treatment was 145 days (range 43 to 1864 days). Flunarizine reduced headache severity (z = -3.354, P = 0.001), monthly frequency (z = -2.585, P = 0.01), and duration (z = -2.549, P = 0.01). Flunarizine was discontinued owing to intolerable adverse effects in a minority (2). Sedation and weight gain were the most common side effects. There were no reports of behavior change or extrapyramidal features. CONCLUSIONS: The most effective management for headaches in patients with Sturge-Weber syndrome has not been established. This retrospective observational study found benefit of flunarizine prophylaxis on headache severity, frequency, and duration in children with Sturge-Weber syndrome without severe side effects. Flunarizine is not licensed for use in the United Kingdom, but these data support its off-license specialist use for headache prophylaxis in Sturge-Weber syndrome.
Subject(s)
Calcium Channel Blockers/pharmacology , Flunarizine/pharmacology , Headache , Paresis , Sensation Disorders , Sturge-Weber Syndrome/complications , Adolescent , Calcium Channel Blockers/administration & dosage , Calcium Channel Blockers/adverse effects , Child , Child, Preschool , Female , Flunarizine/administration & dosage , Flunarizine/adverse effects , Headache/drug therapy , Headache/etiology , Headache/prevention & control , Humans , Male , Paresis/drug therapy , Paresis/etiology , Paresis/prevention & control , Retrospective Studies , Sensation Disorders/drug therapy , Sensation Disorders/etiology , Sensation Disorders/prevention & control , Treatment OutcomeABSTRACT
OBJECTIVE: This study is aimed to access the efficacy and safety of combination therapy of flunarizine plus transcutaneous supraorbital neurostimulation (tSNS) compared with either flunarizine or tSNS alone for migraine prophylaxis. METHODS: Patients with episodic migraine were enrolled and randomized into 3 groups. Flunarizine 5 mg per day, or tSNS for 20 minutes daily or combination of both were prescribed consecutively for 3 months. The primary outcome measures were changes in migraine days and 50% responder rate of monthly migraine days. Secondary outcome measures were the changes in migraine intensity and intake of rescue medication. Finally, satisfaction to treatment and adverse effect were evaluated as well. RESULTS: A total of 154 were randomized and included in the analysis. After 3 months, the monthly migraine days were decreased in 3 groups and more significant in the combination group. The 50% responder rate was significantly higher (78.43%) in the combination therapy than monotherapy of flunarizine (46.15%) or tSNS (39.22%) alone. Greater reduction of migraine intensity and intake of rescue medication was observed in combination group. There was no difference of adverse events between flunarizine group and combination group (P = .89). CONCLUSION: Adding tSNS to flunarizine can improve the therapeutic efficacy of migraine prophylaxis without increasing the adverse effects. In addition, tSNS is effective and safe for migraine treatment and can be a valid option for migraineurs who are reluctant to take oral medications or for patients who experience a low-migraine frequency and/or intensity that prophylactic therapy is not indicated but desire to acquire medical intervention.
Subject(s)
Combined Modality Therapy/methods , Flunarizine/administration & dosage , Migraine Disorders/prevention & control , Transcutaneous Electric Nerve Stimulation/methods , Vasodilator Agents/administration & dosage , Adult , Female , Humans , Male , Middle AgedABSTRACT
Angioneurotic headache is a common nerve headache featured by intermittence, repetition, paroxysm and aggravation, which can severely affect the sufferer's quality of life. Currently, there are multiple drugs which can be used for relieving this type of headache, and the effectiveness and safety of drugs have been a subject of interest in clinical practice. To observe the effects of sibelium in combination with dibazole and offer a basis for the clinical treatment, 136 patients with angioneurotic headache who were admitted to hospital between February and September 2015 were selected and randomly divided into a test group and a control group, 68 in each. Patients in the test group were treated with sibelium in combination with dibazole, while patients in the control group were given sibelium only. The effects, adverse reactions, complications and toxic and side effects of the treatment in the two groups were observed. Furthermore, the blood flow speed and hemodynamic changes before and after treatment were compared. The results demonstrated that the hemodynamic indexes and cerebral blood flow speed of the patients in the test group showed obvious changes after treatment, and the difference was statistically significant (P<0.05); the improvement of the above indexes of the test group was superior to that of the control group, and the difference had statistical significance (P<0.05); the overall effective rate of the test group was higher than that of the control group (94.12% vs 76.47%) (P<0.05); the medication safety of the test group was higher than that of the control group (all P<0.05). It can be concluded that sibelium in combination with dibazole has a remarkable effect in treating angioneurotic headache as it can significantly improve hemodynamic indexes and cerebral blood flow speed. Moreover, the therapy seldom induces toxic and side effects, adverse reactions or complications.
Subject(s)
Benzimidazoles/administration & dosage , Cerebrovascular Circulation/drug effects , Flunarizine/administration & dosage , Headache Disorders , Adult , Benzimidazoles/adverse effects , Female , Flunarizine/adverse effects , Headache Disorders/drug therapy , Headache Disorders/physiopathology , Humans , MaleABSTRACT
OBJECTIVES: Chronic migraine (CM) is a prevalent and devastating disorder with limited therapeutic options. This study explored the efficacy of 10 mg/d flunarizine for CM prophylaxis as compared with 50 mg/d topiramate. METHODS: We conducted a prospective, randomized, open-label, blinded-endpoint trial. Patients with CM were randomized to flunarizine and topiramate treatment. The primary outcomes assessed were the reductions in the total numbers of headache days and migraine days after 8 weeks of treatment. Secondary outcomes were reductions in the numbers of days of acute abortive medication intake and acute abortive medication tablets taken, and the 50% responder rate. RESULTS: Sixty-two subjects were randomized (n=31/group). Patients treated with flunarizine showed significant reductions in the numbers of total headache days (-4.9 vs -2.3, P=.012) and migraine days (-4.3 vs -1.4, P=.001) compared with those treated with topiramate. Patients treated with flunarizine also showed significant reductions in the numbers of days of acute abortive medication intake (-2.3 vs -0.2, P=.005) and acute abortive medication tablets taken (-4.6 vs -0.5, P=.005) and had a higher 50% responder rate in terms of total headache days (58.6% vs 25.9%, P=.013) and migraine days (75.9% vs 29.6%, P=.001), compared with topiramate-treated patients. Flunarizine was generally well tolerated and had a safety profile comparable to that of topiramate. CONCLUSIONS: Our results suggest that, in an 8-week study, 10 mg/d flunarizine is more effective than 50 mg/d topiramate for CM prophylaxis.
Subject(s)
Anticonvulsants/therapeutic use , Flunarizine/therapeutic use , Fructose/analogs & derivatives , Migraine Disorders/drug therapy , Adult , Anticonvulsants/administration & dosage , Anticonvulsants/adverse effects , Double-Blind Method , Female , Flunarizine/administration & dosage , Flunarizine/adverse effects , Fructose/administration & dosage , Fructose/adverse effects , Fructose/therapeutic use , Humans , Male , Middle Aged , Migraine Disorders/prevention & control , TopiramateABSTRACT
El tratamiento preventivo de la migraña está infrautilizado. Además, la adhesión y persistencia al tratamiento son bajas. Sin embargo, es crucial para poder controlar la frecuencia, intensidad y duración de las crisis de migraña, lo que permite a los pacientes un menor uso de analgésicos. Todo esto es clave para mejorar la calidad de vida y discapacidad asociadas. Es importante tener claros los objetivos del tratamiento preventivo, al igual que las indicaciones para iniciarlo, su duración idónea y la adhesión. Mejorar y completar el conocimiento alrededor del tratamiento preventivo probablemente mejorará su prescripción y aportará herramientas que permitan aumentar la adhesión de los pacientes (AU)
The preventive treatment of migraine is under-used. Moreover, treatment compliance and persistence rates are low. Yet, it is crucial to be able to control the frequency, intensity and duration of the attacks of migraine, which enables patients to resort to painkillers less often. All this plays a key role in improving the associated quality of life and disability. It is important to have a clear idea of the goals of preventive treatment, as well as the indications for starting it, its ideal duration and compliance. Enhancing and completing the knowledge we have about preventive treatment will probably improve its prescription and provide tools that allow an increase in patient compliance to be achieved (AU)
Subject(s)
Humans , Headache/prevention & control , Migraine Disorders/drug therapy , Analgesics/administration & dosage , Premedication/methods , Patient Compliance , Adrenergic beta-Antagonists/administration & dosage , Angiotensin Receptor Antagonists/administration & dosage , Valproic Acid/administration & dosage , Flunarizine/administration & dosage , Botulinum Toxins/administration & dosageABSTRACT
BACKGROUND: Non-invasive brain stimulation enables the induction of neuroplasticity in humans, however, with so far restricted duration of the respective cortical excitability modifications. Conventional anodal transcranial direct current stimulation (tDCS) protocols including one stimulation session induce NMDA receptor-dependent excitability enhancements lasting for about 1 h. OBJECTIVE: We aimed to extend the duration of tDCS effects by periodic stimulation, consisting of two stimulation sessions, since periodic stimulation protocols are able to induce neuroplastic excitability alterations stable for days or weeks, termed late phase long term potentiation (l-LTP), in animal slice preparations. Since both, l-LTP and long term memory formation, require gene expression and protein synthesis, and glutamatergic receptor activity modifications, l-LTP might be a candidate mechanism for the formation of long term memory. METHODS: The impact of two consecutive tDCS sessions on cortical excitability was probed in the motor cortex of healthy humans, and compared to that of a single tDCS session. The second stimulation was applied without an interval (temporally contiguous tDCS), during the after-effects of the first stimulation (during after-effects; 3, or 20 min interval), or after the after-effects of the first stimulation had vanished (post after-effects; 3 or 24 h interval). RESULTS: The during after-effects condition resulted in an initially reduced, but then relevantly prolonged excitability enhancement, which was blocked by an NMDA receptor antagonist. The other conditions resulted in an abolishment, or a calcium channel-dependent reversal of neuroplasticity. CONCLUSION: Repeated tDCS within a specific time window is able to induce l-LTP-like plasticity in the human motor cortex.
Subject(s)
Evoked Potentials, Motor/physiology , Long-Term Synaptic Depression/physiology , Motor Cortex/physiology , Transcranial Magnetic Stimulation , Administration, Oral , Adult , Analysis of Variance , Calcium Channel Blockers/administration & dosage , Dextromethorphan/administration & dosage , Evoked Potentials, Motor/drug effects , Excitatory Amino Acid Antagonists/administration & dosage , Female , Flunarizine/administration & dosage , Humans , Long-Term Synaptic Depression/drug effects , Male , Time Factors , Young AdultABSTRACT
PURPOSE: Cognitive impairment is observed commonly in children with a history of infantile spasms (IS). The goal of this study was to prospectively examine the effect on cognitive outcome of a neuroprotective agent used as adjunctive therapy during treatment of the spasms. METHODS: In a randomized controlled trial, patients received a standardized therapy plus flunarizine or placebo. The standardized treatment consisted of vigabatrin as first-line therapy. Nonresponders were switched to intramuscular synthetic adrenocorticotropic hormone (sACTH depot) after 2 weeks and, if necessary, to topiramate after two additional weeks. The Vineland Adaptive Behavior Scale (VABS) and Bayley Scales of Infant Development (BSID) were used as outcome measures 24 months after the intervention. KEY FINDINGS: Sixty-eight of 101 children diagnosed over 3 years in seven centers in Canada received either adjunctive flunarizine or placebo. Sixty-five of the 68 children (96%) became spasm-free within 8 weeks and no late relapse occurred. Bayley and Vineland results were available at baseline and at 24 months in 45 children. There was no significant difference in the BSID developmental quotient between the flunarizine- and placebo-treated children at baseline (44.3 ± 35.5 vs. 30.9 ± 29.8; p = 0.18) or 24 months later (56.9 ± 33.3 vs. 46 ± 34.2; p = 0.29). However, the 10 flunarizine-treated children with no identified etiology had a better outcome than the eight controls at 24 months on both the Vineland Scale (84.1 ± 11.3 vs. 72.3 ± 9.8; p = 0.03) and the Bayley Scale (87.6 ± 14.7 vs. 69.9 ± 25.3; p = 0.07). SIGNIFICANCE: Our study failed to demonstrate a protective effect of flunarizine on cognitive outcome in a cohort of children with IS. An analysis of subgroups suggested that flunarizine may further improve cognitive outcome in children with no identified etiology.
Subject(s)
Anticonvulsants/administration & dosage , Cognition Disorders/drug therapy , Cognition Disorders/epidemiology , Flunarizine/administration & dosage , Spasms, Infantile/drug therapy , Spasms, Infantile/epidemiology , Cognition Disorders/psychology , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Infant , Male , Spasms, Infantile/psychology , Treatment OutcomeABSTRACT
OBJECTIVES: The objective of this study was to observe the efficacy, safety, and side effects of a combination of flunarizine plus topiramate compared with either flunarizine and or toparamate alone for migraine prophylaxis. METHODS: Out of 150 patients with migraine recruited into the study and randomly assigned to one of three conditions, 126 completed the trial in their group: flunarizine (39), topiramate (44), and flunarizine plus topiramate (43). Patient information was assessed at enrollment and at follow-up visits at the end of months 1-3, 6, 9, and 12. The primary measure of efficacy reduction in mean monthly migraine frequency of at least 50% as compared with baseline. Secondary efficacy parameters included reduction in mean monthly migraine days and severity of headache. Side effects were compared in the three groups by recording adverse reactions and weight changes. RESULTS: The proportion whose monthly headache frequency decreased more than 50% was 66.7% (26/39) in the flunarizine group, 72.7% (32/44) in the topiramate group and 76.7% (33/43) in the combination group, respectively (P=0.593). The mean monthly days and severity of headache in the three groups also declined and was more significant in the flunarizine plus topiramate group than in the flunarizine group and the topiramate group (P<0.05). In the flunarizine group, the average weight change was 0.6kg. Topiramate was associated with a mean weight loss was of -0.9kg in the topiramate group and -0.2kg in the flunarizine plus topiramate group. CONCLUSION: Flunarizine, topiramate, and the combination of flunarizine with topiramate are all effective and have good tolerability in migraine prophylaxis. Adding topiramate to flunarizine may reduce the latter's impact on body weight.
Subject(s)
Flunarizine/administration & dosage , Fructose/analogs & derivatives , Migraine Disorders/drug therapy , Migraine Disorders/prevention & control , Adolescent , Adult , Aged , Drug Therapy, Combination , Female , Follow-Up Studies , Fructose/administration & dosage , Humans , Male , Middle Aged , Migraine Disorders/epidemiology , Prospective Studies , Topiramate , Treatment Outcome , Young AdultABSTRACT
OBJECTIVES: This study was designed to document the effects 10 mg flunarizine, administrated in the preoperative period, on postoperative morphine requirement and analgesic quality, in abdominal surgery. METHODS: Thirty patients, aged 18 to 55 years, were studied. Patients were randomly allocated to one of two equally sized groups, and received either 2 capsules of 5 mg flunarizine (Group I) or 2 placebo capsules (Group II) 2 hours before the operation, immediately after the extubation and at the 15th minute, Aldrete postanesthesia recovery scores were assessed. In the postoperative period, patients were connected to a patient-controlled analgesia device for intravenous morphine, and the first analgesic requirement time was recorded. Ramsay sedation scale, visual analogue pain scale and morphine consumption were assessed after the extubation. RESULTS: Systolic arterial pressures at the 5th minute of the preoperative period were significantly lower in the flunarizine group than placebo group. Heart rates in the 45th minute were also lower in the flunarizine group. Flunarizine patients reported statistically lower visual analogue pain scale values in the postoperative 12th hour. There was no significant difference in postoperative sedation scores between the groups. Flunarizine did not lengthen the first analgesic requirement time and similarly did not lessen the morphine requirement. CONCLUSION: We conclude that 10 mg flunarizine administered in the preoperative period had no significant effects on clinical parameters, had no analgesic effect and did not augment the analgesic effects of morphine at this dose.
Subject(s)
Analgesics, Opioid/administration & dosage , Anticonvulsants/administration & dosage , Flunarizine/administration & dosage , Morphine/administration & dosage , Pain, Postoperative/drug therapy , Abdominal Wall/surgery , Adolescent , Adult , Analgesia, Patient-Controlled , Anesthesia Recovery Period , Drug Administration Schedule , Female , Humans , Infusions, Intravenous , Male , Middle Aged , Pain Measurement , Preoperative Period , Treatment OutcomeABSTRACT
Alternating hemiplegia of childhood (AHC) is a rare neurological disorder which usually presents before 18 months of age and is characterised by recurrent alternating episodes of hemiparesis. A single effective treatment for this condition is yet to be established; flunarizine is currently the most widely used but with varying degrees of success. An 18-month-old child presented with AHC and treatment with a combination of topiramate and flunarizine made a significant difference in controlling the frequency and severity of the attacks. This possibly allowed a better developmental outcome than in most children with this condition. Topiramate combined with flunarizine for treating AHC has much potential for further research.
Subject(s)
Anticonvulsants/administration & dosage , Flunarizine/administration & dosage , Fructose/analogs & derivatives , Fructose/administration & dosage , Hemiplegia/drug therapy , Humans , Infant , Male , Topiramate , Treatment OutcomeABSTRACT
AIM: To evaluate the efficacy and tolerability of flunarizine, a nonselective calcium channel blocker, on intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). DESIGN: Randomized, placebo-controlled, double blind, cross-over phase II trial. METHODS: Ten patients diagnosed with bilateral OAG or OH were included. Each patient served as his own control. On the first study visit, 1 drop of either 0.05% flunarizine or placebo was applied in the study eye. Patients were followed-up during 6 hours (0, 15, 30, and 60 min, 2, 3, 4, and 6 h) for vital signs, slit lamp examination, corneal fluorescein staining, and IOP. After a wash-out period of 4 weeks, 1 drop of either placebo or flunarizine was applied in the same eye and patients were followed-up for another 6 hours. RESULTS: The flunarizine group showed a statistically significant decrease from baseline at T2, T3, T4, and T6 hours (P=0.01, P=0.03, P=0.01, and P=0.03, respectively). No significant difference in IOP decrease from baseline (P>0.06) was observed between the 2 groups. There was no statistically significant difference in all of the following parameters: limbal hyperemia, bulbar or palpebral conjunctival hyperemia, corneal staining with fluorescein, best-corrected visual acuity, comfort of eye drops, and vital signs. CONCLUSIONS: The absence of a statistically significant difference in IOP reduction between the 2 groups may be due to the small number of patients included. However, a single dose of 0.05% flunarizine significantly reduced IOP when compared with baseline values, whereas this was not observed with placebo.
Subject(s)
Calcium Channel Blockers/administration & dosage , Flunarizine/administration & dosage , Glaucoma, Open-Angle/drug therapy , Intraocular Pressure/drug effects , Administration, Topical , Blood Pressure/drug effects , Calcium Channel Blockers/adverse effects , Cross-Over Studies , Double-Blind Method , Female , Flunarizine/adverse effects , Humans , Male , Middle Aged , Ocular Hypertension/drug therapy , Pilot Projects , Tonometry, Ocular , Treatment OutcomeABSTRACT
PURPOSE: To evaluate the effect of intravitreal injection of N-methyl-D-aspartate (NMDA) on brain-derived neurotrophic factor (BDNF), pituitary adenylate cyclase-activating peptide-38 (PACAP-38), vasoactive intestinal peptide (VIP) and the VIP-associated glial protein activity-dependent neuroprotective protein (ADNP) in the rat retina. These elements have well-documented neuroprotective properties and may thus be integrated in endogenous neuroprotective mechanisms in the retina which break down in NMDA excitotoxicity. METHODS: A volume of 2 µl of 100 nmol NMDA was intravitreally injected into one eye of rats, the untreated eye served as a control. Time-dependent effects of NMDA on VIP, PACAP-38 and BDNF were detected by radioimmunoassay and ELISA, and the effect on the expression of VIP, PACAP-38 and ADNP was evaluated by quantitative RT-PCR 20 days after NMDA injection. Topical flunarizine served to find out whether the effect of NMDA is counteracted. RESULTS: Compared to PACAP-38, VIP levels significantly decreased on days 1, 7, 14, 28 and 56 after NMDA injection indicating that VIPergic cells are more vulnerable than PACAP-38-expressing cells. The expression of VIP and ADNP but not of PACAP-38 was found to be reduced, and application of topical flunarizine counteracted the decrease of VIP. BDNF levels significantly increased after days 1 and 3. CONCLUSION: The early upregulation of BDNF seems to act neuroprotectively and leads to a delay of ganglion cell loss. Although there is no direct evidence, the decrease of VIP and ADNP - the consequence of the presence of NMDA receptors on these peptide-expressing cells - might contribute to the breakdown of endogenous neuroprotective mechanisms given that the decrease of the VIP-related ADNP runs in parallel with the decrease of VIP. Activating and maintaining these mechanisms must be the primary aim in the therapy of diseases with retinal neuronal degeneration.
Subject(s)
Brain-Derived Neurotrophic Factor/metabolism , Excitatory Amino Acid Agonists/toxicity , N-Methylaspartate/toxicity , Nerve Tissue Proteins/metabolism , Neuropeptides/metabolism , Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism , Retina/drug effects , Vasoactive Intestinal Peptide/metabolism , Animals , Brain-Derived Neurotrophic Factor/genetics , Enzyme-Linked Immunosorbent Assay , Flunarizine/administration & dosage , Intravitreal Injections , Male , Nerve Tissue Proteins/genetics , Neuropeptides/genetics , Oligopeptides , Pituitary Adenylate Cyclase-Activating Polypeptide/genetics , Radioimmunoassay , Rats , Rats, Sprague-Dawley , Real-Time Polymerase Chain Reaction , Retina/metabolism , Up-Regulation , Vasoactive Intestinal Peptide/geneticsABSTRACT
Hypnic headache (HH) is a primary headache disorder, which occurs exclusively during sleep and usually begins after 50 years of age. There are no controlled trials for the treatment of HH. We reviewed all the available papers, including 119 cases published in literature up to date, reporting the efficacy of the medications used to treat HH. Acute treatment is not recommended, since no drug proved to be clearly effective and also because the intensity and the duration of the attacks do not require the intake of a medication in most cases. As for prevention, a wide variety of medications were reported to be of benefit in HH. The drugs that were found to be effective in at least five cases are: lithium, indomethacin, caffeine and flunarizine. Lithium was the most extensively studied compound and demonstrated to be an efficacious treatment in 32 cases. Unfortunately, despite its efficacy, significant adverse effects and poor tolerability are not rare, mainly in elderly patients. Many patients reported a good response to indomethacin, but some could not tolerate it. Caffeine and melatonin treatments did not yield robust evidence to recommend their use as single preventive agents. Nevertheless, their association with lithium or indomethacin seems to produce an additional therapeutic efficacy. A course of lithium should be tried first, followed 3-4 months later by tapering. If headache recurs during tapering, a longer duration of therapy may be needed. If lithium treatment does not provide a significant response, indomethacin can be commenced as second-line approach. If these treatments prove to be ineffective or poorly tolerated, other agents, such as caffeine and melatonin, can be administered.
Subject(s)
Headache Disorders, Primary/drug therapy , Headache Disorders, Primary/prevention & control , Lithium Compounds/administration & dosage , Antimanic Agents/administration & dosage , Antimanic Agents/adverse effects , Antimanic Agents/therapeutic use , Caffeine/administration & dosage , Caffeine/adverse effects , Caffeine/therapeutic use , Flunarizine/administration & dosage , Flunarizine/adverse effects , Flunarizine/therapeutic use , Headache Disorders, Primary/complications , Humans , Indomethacin/administration & dosage , Indomethacin/adverse effects , Indomethacin/therapeutic use , Lithium Compounds/adverse effects , Lithium Compounds/therapeutic useABSTRACT
The aim of this study was to investigate the effects of intravenous administration of flunarizine on the diameter of retinal blood vessels and blood pressure in anesthetized rats and to compare the effects of this antagonist with those of nicardipine and nifedipine. Retinal vascular images were captured with a fundus camera system for small animals and the diameter of retinal blood vessels contained in the images was measured using image-processing softwares on a personal computer. Blood pressure was continuously measured. Flunarizine [1-30 microg/kg, intravenously (i.v.)] dose-dependently increased the diameter of retinal blood vessels without significantly changing systemic blood pressure. Nicardipine (1-30 microg/kg, i.v.) increased the retinal blood vessel diameter but decreased blood pressure in a dose-dependent manner. Nifedipine (10-100 microg/kg, i.v.) failed to dilate the retinal blood vessels, although it produced comparable depressor responses as those to nicardipine. These results suggest that flunarizine selectively acts on the retinal blood vessels rather than on the peripheral resistance vessels. Flunarizine could therefore be considered as a candidate for therapeutic drugs to treat diseases associated with disorders of retinal circulation without severe cardiovascular side-effects.
Subject(s)
Blood Pressure/drug effects , Flunarizine/pharmacology , Retinal Artery/drug effects , Retinal Vein/drug effects , Vasodilator Agents/pharmacology , Anesthesia , Animals , Dose-Response Relationship, Drug , Flunarizine/administration & dosage , Male , Nifedipine/pharmacology , Rats , Rats, Wistar , Vasodilator Agents/administration & dosageABSTRACT
Calcium channel antagonists have been employed in the prophylactic treatment of migraine. Their major action is the inhibition of Ca2+ influx into smooth muscle cells that is mediated through high voltage-sensitive Ca2+ channels. These drugs had been introduced for the treatment of migraine mainly because of 2 of their effects were considered to be of potential benefit to these patients: their vasodilatory effect and their protective action against the harmful effects of hypoxia on cerebral issue. However, recent studies have provided evidence that in the central nervous system, they directly affect neuronal functions known to be calcium-dependent, such as neurotransmitter synthesis and release, inhibition of cortical spreading depression, and neuronal excitability. Although the exact mechanism of prophylactic effects calcium channel antagonists against migraine attacks remains unknown, alterations in Ca2+ channel function in the central nervous system are believed to play a key role in prophylaxis of migraine.